Biofrontera AG (LTS:0DOL) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0DOL Biofrontera AG LTS:0DOL
16 GF Score
Price €2.28
GF Value €2.41
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Biofrontera AG FFO per Share?

FFO per Share only applies to REITs.

LTS:0DOL
16GF Score
Biofrontera AG LTS:0DOL
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biofrontera AG (LTS:0DOL) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued. The current stock price of €2.28 is trading 5.4% below its estimated GF Value™ of €2.41. GuruFocus considers Biofrontera AG to be Fairly Valued.

Key valuation signals for LTS:0DOL:

  • FFO per Share:
  • GF Value™: €2.41 vs. price of €2.28 (5.4% below fair value)
  • GF Score™: 16/100 with 4 warning signs

No single metric tells the full story. See the LTS:0DOL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biofrontera AG Business Description

Other Exchanges B8FK:Germany
Address Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
16GF Score

Get the complete analysis for LTS:0DOL

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.28
Price
€2.41
GF Value